B7-2 Antibody (GL1): sc-52448

B7-2 Antibody (GL1) is a rat monoclonal IgG2a antibody that detects B7-2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). B7-2, also known as CD86, plays a crucial role in the immune response by acting as a costimulatory molecule on antigen-presenting cells, where B7-2 binds to CD28 and CTLA-4 on T cells, thereby enhancing T cell activation and proliferation. This interaction is vital for the effective activation of T cells, which are essential for adaptive immunity. The structure of B7-2 is characterized by immunoglobulin-like domains, which facilitate binding to T cell receptors, and B7-2 expression is tightly regulated during immune responses. Understanding the structural features of B7-2 is important because alterations in B7-2 expression or function can lead to immune dysregulation, contributing to various autoimmune diseases and affecting the efficacy of immunotherapies. Anti-B7-2 antibody (GL1) is an invaluable tool for researchers studying T cell activation and the intricate signaling pathways involved in immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

B7-2 Antibody (GL1) References:

1. B cell receptor- and beta 2-adrenergic receptor-induced regulation of B7-2 (CD86) expression in B cells.  |  Kohm, AP., et al. 2002. J Immunol. 168: 6314-22. PMID: 12055247
2. Different cell surface oligomeric states of B7-1 and B7-2: implications for signaling.  |  Bhatia, S., et al. 2005. Proc Natl Acad Sci U S A. 102: 15569-74. PMID: 16221763
3. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.  |  Shrestha, P., et al. 2021. PLoS Pathog. 17: e1009091. PMID: 33411730
4. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.  |  Hodge, JW., et al. 1994. Cancer Res. 54: 5552-5. PMID: 7522961
5. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.  |  Kuchroo, VK., et al. 1995. Cell. 80: 707-18. PMID: 7534215
6. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro.  |  Levine, BL., et al. 1995. Int Immunol. 7: 891-904. PMID: 7577797
7. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype.  |  Creery, WD., et al. 1996. Eur J Immunol. 26: 1273-7. PMID: 8647204
8. Analysis of B7-1 and B7-2 costimulatory ligands in cultured mouse microglia: upregulation by interferon-gamma and lipopolysaccharide and downregulation by interleukin-10, prostaglandin E2 and cyclic AMP-elevating agents.  |  Menèndez Iglesias, B., et al. 1997. J Neuroimmunol. 72: 83-93. PMID: 9003248
9. Expression of B7-1 and B7-2 costimulatory molecules by human gastric epithelial cells: potential role in CD4+ T cell activation during Helicobacter pylori infection.  |  Ye, G., et al. 1997. J Clin Invest. 99: 1628-36. PMID: 9120006
10. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD).  |  Rugtveit, J., et al. 1997. Clin Exp Immunol. 110: 104-13. PMID: 9353156

The preferred B7-2 antibody is B7-2 Antibody (D-6): sc-28347.